Printer Friendly

FDA warns on Internet ads.

The Food and Drug Administration has warned 14 drug makers against using brief Internet ads to promote drugs, saying the ads are misleading because they fail to provide full information about risks and indications. The ads typically appear on search engines, such as Google, as "sponsored links" when patients search for information on medical conditions. The ads cited by the FDA include promotions for the multiple sclerosis drug Tysabri (natalizumab), the cardiovascular drug Plavix (clopidogrel), and the diabetes treatment Avandia (rosiglitazone). The sponsored links generally contain only a dozen or so words--not enough to convey detailed treatment or risk information, according to the FDA. The Pew Prescription Project, a nonprofit drug-safety group, has asked the FDA to articulate the rules regulating online advertising and to advise manufacturers on where risk disclosures may appear in Internet ads.
COPYRIGHT 2009 International Medical News Group
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2009 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:POLICY & PRACTICE
Author:Anderson, Jane
Publication:Internal Medicine News
Article Type:Brief article
Geographic Code:1USA
Date:May 1, 2009
Previous Article:Massachusetts clinics are busy.
Next Article:FDA seeks data on older devices.

Related Articles
Taking on big pharma - and the FDA: the fight against federal preemption is far from over, but some courts have rejected drug company claims that an...
Wyeth v. Levine sets up a showdown in the preemption corral.
Bioidentical hormones, estriol, and the FDA.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters